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Endothelial cellsVersican is a proteoglycan expressed in the extracellular matrix, where it regulates a variety of cell
activities and affects tumor development. With alternative splicing, there are four versican iso-
forms, denoted V0, V1, V2 and V3. The V2 isoform is highly expressed in the mature brain but its
function in the mature brain has not yet been elucidated. Since brain tumors are among the most
angiogenic of human tumors, we investigated whether or not the V2 isoform plays a role in angio-
genesis and found that the glioblastoma cell line U87 stably transfected with V2 formed tumors con-
taining extensive vasculature. Although the V2-expressing cells grew slowly, they survived well in
serum-free medium. They also displayed high adhesive ability to endothelial cells and facilitated
tube-like structure formation. Importantly, ﬁbronectin was up-regulated by V2 and mediated V2
function. Thus, versican V2 could be a potential target for intervention of brain tumor angiogenesis.
 2012 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Glioblastomas are among the most life-threatening brain
tumors due to their invasive and inﬁltrative character. Through a
process known as angiogenesis, glioblastomas stimulate the for-
mation of new blood vessels, which are structurally and function-
ally abnormal. Glioblastomas are among the most angiogenic
human tumors. High-grade glioblastomas are characterized by
more extensive vascularization than low-grade glioblastomas.
The degrees of neovascularization in high-grade glioblastomas
are a histological indicator of malignancy and patient prognosis.
As a consequence of extensive angiogenesis, a hostile microenvi-
ronment containing low oxygen tension and high interstitial ﬂuid
pressure leads to a more malignant phenotype associated with in-
creased morbidity and mortality. We hypothesize that malignant
tumor cells are capable of controlling endothelial cell activities
by modulating the expression of extracellular matrix molecules
within the tumor microenvironment.
Versican is a hyaluronan-binding protein that belongs to a class
of the large aggregating chondroitin sulfate proteoglycans locatedprimarily in the extracellular matrix [1]. By alternative splicing of
two exons encoding chondroitin sulfate attachment sequences
(CSa and CSb domains), there exist four versican isoforms [2–4].
These four isoforms include the largest isoform (versican V0),
which is not subject to alternative splicing and contains both the
CSa and CSb domains; versican V1, the larger of the alternatively
spliced forms, which has the b domain for chondroitin sulfate
attachment [5]; versican V2, the smaller of the alternatively spliced
forms, which contains the b domain; and versican V3, which con-
tains neither of the CS sequences. Versican V0 has a core protein
of 3650 amino acids [3]. Versican V0 is synthesized by prechondro-
genetic mesenchymal cells and plays a role in cell migration [3,6].
Versican V1 is synthesized by embryo and endothelial cells, con-
tributing to cell proliferation and tumor growth [7,8]. Versican
V2 is expressed in mature tissues and can induce cell apoptosis
and repress tumor growth [2,7]. Versican V3 is expressed in vari-
ous mouse and human tissues and can inhibit tumor growth [9–
11]. While the functions of versican have been reported in different
cell types and tissues [12–15], different isoforms also play different
functions [7,16,17].
Versican is highly expressed in the early stages of development,
but becomes downregulated after tissue maturation [5]. In the
adult human central nervous system, versican is expressed mainly
in the white matter of the frontal lobe, cerebellum, brain stem, and
spinal cord, in close association with astrocytes and oligodendro-
cytes [18–21]. Interestingly, during wound repair or tumor
formation, versican expression is again upregulated [22–26].
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mor formation [27–30]. Versican is detected in interstitial tissues
at the invasive margins of tumors, and in the perivascular elastic
tissues associated with tumor invasion [26]. Increased versican
immunostaining has been detected during tumor blood vessel for-
mation [29]. It appears that V0 is the key isoform in the early
stages of tissue development. The V1 isoform plays central roles
in cell proliferation and tumor growth, while the V2 and V3 iso-
forms inhibit cell proliferation and tumor growth. Since the V2 iso-
form is the major isoform expressed in brain tissues, and brain
tumors have been shown to be greatly enriched in vascularization,
we hypothesized that the V2 isoform may play a role in brain tu-
mor angiogenesis. By in vitro and in vivo approaches, this study
was designed to test the role of the versican V2 isoform in
angiogenesis.
2. Methods
2.1. Cell proliferation assay
Glioblastoma cell line U87 cells stably transfected with versican
V2 isoform or a control vector (1  105 cells) were seeded onto
6-well tissue culture plates in 10% FBS/DMEM medium and main-
tained at 37 C overnight. Cells were harvested daily and cell
number was determined by a Coulter Counter.
2.2. Cell survival assay
Cells (1.5  105 cells per well or 2  105 cells per well) were
seeded on 6-well tissue culture plates in 10% FBS/DMEM. Next
day, the medium was removed and the culture were washed with
PBS and replaced with serum-free DMEM. The cultures were incu-
bated for different time periods. The cell numbers were counted by
using trypan blue staining as described [31,32]. The experiments
were repeated three times.
2.3. Cell cycle analysis
U87 cells stably transfected with V2 or the control vector were
cultured overnight. The cells were then harvested, washed, and
resuspended in cold PBS and incubated in ice-cold 70% ethanol
for 3 h. The cells were then centrifuged at 1,500 rpm for 10 min
and resuspended in propidium iodide (PI) master mix (40 mg/ml
PI and 100 mg/ml RNase in PBS) at a density of 5  105 cells/ml
and incubated at 37 C for 30 min before analysis with ﬂow
cytometry.
2.4. Tube formation assay
Vector- or V2-transfected U87 cells were grown to 80% conﬂu-
ency and then harvested from the plates by 0.05% trypsin with
0.53 mM EDTA. The cells were recovered by centrifugation, washed
three times with DMEM, suspended in this medium at a density of
4  104 cells/ml, and mixed with endothelial cells EOMA or YPEN.
The mixture was inoculated to Matrigel-coated 8-chamber culture
slides. Formation of tube-like structure was examined under a light
microscope and photographed.
2.5. Co-culture experiments
The V2- or vector-transfected-cells were mixed with YPEN or
EOMA cells (1.5  105 cells/ml for each) and seeded on 3.5-cm cul-
ture dishes in DMEM supplemented with 10% FBS (2 ml). The cul-
tures were maintained for 5 days. The interaction of both types of
cells were examined with light and ﬂuorescent microscopy.2.6. Western blotting
Cell lysates were prepared from V2- or vector-transfected cells
seeded on 6-well plates at 106 cells/well by lysing the cells in each
well with 100 ll lysis buffer containing Triton X-100, SDS, and pro-
tease inhibitors. Protein concentrations were measured by Bio-Rad
Protein Assay kit. Lysates containing 50 lg protein were subjected
to SDS-PAGE. The separated proteins were transferred to a nitrocel-
lulose membrane followed by immunostaining with a primary
antibody against ﬁbronectin (BD Transduction Laboratories
610078) or versican (US Biological L1350) overnight at 4 C. Next
day, the membrane was washed and incubated with HRP-
conjugated goat-anti-mouse secondary antibody for 2 h at room
temperature followed by ECL detection. After detection of protein
bands, the blot was re-probed with anti-b-actin antibody to
conﬁrm equal loading of samples.
2.7. Tumorigenicity assays in nude mice and immunohistochemistry
analysis
Five-week-old CD1 strain nude mice were injected subcutane-
ously with V2- or vector-transfected U87 cells (5  106 cells per
mouse) using the methods described previously [33]. When the
sizes of the tumors reached the limited size set by the Animal Care
Committee of Sunnybrook Research Institute, the mice were sacri-
ﬁced for tumor harvest. Organs were freshly excised and ﬁxed in
formalin overnight, immersed in 70% ethanol, embedded in paraf-
ﬁn, and sectioned by a microtome (Leica RM2255). The sections
were de-parafﬁnized with xylene and ethanol and then boiled in
a pressure cooker. After washing with Tris-Buffered-Saline (TBS)
containing 0.025% Triton X-100, the sections were blocked with
10% goat serum and incubated with primary antibodies against
CD34, versican or ﬁbronectin in TBS containing 1% bovine serum
albumin (BSA) overnight. The sections were washed and labeled
with biotinylated secondary antibody, followed by avidin conju-
gated horse–radish peroxidase provided by the Vectastain ABC
kit (Vector, PK-4000). The staining was developed by DAB kit (Vec-
tor, SK-4100). The slides were subsequently stained with Mayer’s
Hematoxylin for counter staining followed by slide mounting.
2.8. Statistical analysis
The results (mean values ± SD) of all the experiments were sub-
ject to statistical analyses by two-tailed t-test. The level of signiﬁ-
cance was set at P < 0.05, and P < 0.01.
3. Results and discussion
3.1. Versican V2 enhances angiogenesis
U87 glioblastoma cells stably transfected with a versican V2
expression construct or a control vector, were subcutaneously in-
jected into nude mice. Six weeks after injection, the mice were sac-
riﬁced. The tumors formed by the V2-transfected cells were visibly
enriched in vascularisation, whereas the tumors formed by the
vector-transfected cells did not exhibit this phenotype (Fig. 1A).
During retrieval of the tumors, we found that the V2 tumors were
very adhesive to mouse tissues and a high level of vascularity was
observed at the site of tumor growth. By H & E staining of tumor
sections, it was observed that a large number of red blood cells
could be detected in the V2 tumors, but not in the control tumors
(Fig. 1B).
To examine blood vessel formation, we immuno-stained the tu-
mor sections to detect expression of CD34, an endothelial marker
of blood vessel formation. The number of blood vessels in each
Fig. 1. Expression of versican V2 isoform enhances angiogenesis. (A) U87 cells (5  106) stably transfected versican V2 isoform or a control vector were injected
subcutaneously into CD-1 nude mice. Tumors were removed from the mice 4 weeks after the injection. Tumors formed by the V2-transfected cells showed increased
vasculature compared to those formed by the control cells; (B) tumors formed by cells transfected with V2 isoform (V2 tumors) or a control vector were subjected to H & E
staining. Extensive bleeding was detected in the V2 tumors, but not in the control tumors; (C) the tumor sections were subject to immunohistochemistry probed with anti-
CD34 antibody to detect blood vessel formation. The number of blood vessels was counted in 10 randomly selected imaging ﬁelds and statistically analyzed. Expression of V2
promoted blood vessel formation as compared with the control. n = 5; (D) typical images of blood vessels from each mouse are shown; (E) tumor lysates were analyzed on
Western blot to conﬁrm that the tumor cells were transfected with the versican expression construct; (F) tumor sections were also subject to immunohistochemistry to
conﬁrm expression of the versican expression construct.
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and analyzed statistically. Signiﬁcantly more vascular structures
were detected in the V2 tumors than in the control tumors
(Fig. 1C). Careful examination of the structures of each blood vessel
did not reveal obvious structural differences between the V2 and
control tumors. Typical blood vessel structures from each of the tu-
mors are shown (Fig. 1D). We conﬁrmed expression of the V2 con-struct within tumors formed by the V2-transfected cells using
Western blotting (Fig. 1E) and immunohistochemistry (Fig. 1F).
3.2. Versican V2 reduces tumor proliferation but enhances survival
To test how the versican V2 isoform affected tumor cell activi-
ties, we initially determined proliferation rates of U87 cells stably
Fig. 2. Expression versican V2 slows down cell proliferation but enhances survival. (A) U87 cells stably transfected with versican V2 isoform or a control vector were seeded
on tissue cultures plates containing 10% FBS for six days for proliferation assays. Expression of V2 slowed cell proliferation. ⁄⁄P < 0.01. Error bars, SEM (n = 4); (B) the cells were
also seeded on tissue cultures plates in serum-free medium. The number of living cells was counted with trypan blue staining using a haematocytometer for the duration of
six days. Expression of V2 enhanced cell survival. ⁄⁄P < 0.01. Error bars indicate SEM (n = 4); (C) the cells were also subjected to cell cycle analysis. An increased number of V2
cells were detected in the G1 phase as compared with the control cells; (D) the culture medium was subject to western blot analysis for versican expression to conﬁrm
secretion of the versican product.
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Fig. 3. Expression versican V2 promotes cell–cell interaction and tube-like structure formation. (A) V2- and vector-transfected cells were co-cultured with endothelial cells
EOMA at a 1:1 ratio. After 5 days, the co-cultured cells were photographed. The V2 cells displayed higher capacities in interaction with EOMA cells than the control cells. As a
result, there was closed contact between the V2 cells and EOMA cells compared with the control cells; (B) V2- and vector-transfected cells were co-cultured with YPEN
endothelial cells at a ratio of 1:1. After 5 days, the co-cultured cells were photographed. YPEN cells could mix well with V2 expressing U87 cells, but not the control cells; (C)
V2- and vector-transfected cells were mixed with YPEN cells and inoculated in Matrigel, followed by examination of tube formation. The YPEN cells formed complex tube-like
structures when mixed with the V2 cells, but not with the control cells; (D) typical photographs of tube-like structures are shown; (E) V2- and vector-transfected cells were
mixed with EOMA cells for tube formation assay. Similarly, the EOMA cells formed complex tube-like structures when mixed with the V2 cells, but not with the control cells.
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transfected with V2 grew much slower relative to the control cells
(Fig. 2A). In soft agar, the V2-transfected cells formed smaller col-
onies than the control cells (Supplementary Fig. S1). We thus con-
ducted an analysis of cell cycle progression and observed that more
V2-transfected cells were detected in the G1 phase than in the G2
or S phases (Fig. 2B). This result indicated that the V2 cells turned
over slower than the control cells, conﬁrming the anti-proliferative
function of versican V2.
We also tested whether or not expression of V2 affected cell
survival. The cells were cultured in serum-containing DMEM over-night. The next day, the culture media was removed and the cells
were cultured in serum-free medium. The overnight culture in ser-
um-containing medium allowed the cells to intake serum and
growth factors, resulting in continued growth. Continued culturing
without serum however resulted in cell detachment and cell death.
Interestingly, while the V2-transfected cells grew slower than the
control cells, they displayed a much greater capacity to survive
in serum free conditions and resist serum-free-induced cell
detachment and cell death (Fig. 2C). Secretion of the V2 product
was conﬁrmed on Western blot by using the culture medium har-
vested from the V2-transfected cells (Fig. 2D).
Fig. 4. V2 upregulates ﬁbronectin expression. (A) cell lysates prepared from V2- and vector-transfected cells or from the parental cells U87 were subject to western blot
analysis probed with anti-ﬁbronectin antibody. The same membranes were also probed with anti-b-actin antibody serving as a loading control. Expression of V2 construct
increased ﬁbronectin levels compared with the vector-transfected cells or the U87 cells; (B) culture medium was analyzed by Western blotting for ﬁbronectin levels. The cells
transfected with the V2 construct secreted larger amounts of ﬁbronectin than the control cells; (C) tumor lysates were analyzed on Western blot for ﬁbronectin expression.
Transfection with the V2 construct increased ﬁbronectin level; (D) tumor sections were subject to immunohistochemistry to conﬁrm up-regulation of ﬁbronectin expression
in the tumors formed by the V2-transfected cells; (E) cell lysates prepared from siRNA constructs targeting ﬁbronectin were analyzed on Western blot and probed with an
anti-ﬁbronectin antibody, conﬁrming silencing of ﬁbronectin; (F) cells transfected with siFN-32 or a control vector were mixed with YPEN cells, followed by inoculation in
Matrigel for tube formation assay. Transfection with siFN-32 decreased the complexity of the tube-like structures; (G) cells transfected with siFN-32 or a control vector were
also mixed with EOMA cells for tube formation assay. Silencing ﬁbronectin decreased the formation of tube-like structures; (H) typical photographs of tube-like structures
formed by EOMA cells mixed with cells transfected with siFN-32 or a control vector are shown.
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W. Yang, A.J. Yee / FEBS Letters 587 (2013) 185–192 1913.3. V2 expression facilitates endothelial-tumor cell interaction
Subcutaneous injection into nude mice revealed that the tu-
mors formed by V2-expressing cells harbored signiﬁcantly more
blood vessels than those formed by control cells. We examined
whether the V2-expressing cells and the control cells might display
differential capacities in interacting with endothelial cells, the ma-
jor component of blood vessels. U87 cells transfected with or with-
out the V2 construct were mixed with EOMA mouse endothelial
cells and inoculated into tissue culture plates. The cells were co-
cultured for ﬁve days. Cell–cell interactions were examined care-
fully by light microscopy. We found that EOMA cells, when mixed
with the vector-transfected cells or the parental cells, tended to
grow as colonies, with a clear delineation between the two cell
types (Fig. 3A). In contract, the V2-expressing U87 cells showed
high levels of interaction with EOMA cells. These results indicated
that the V2-expressing cells had a high afﬁnity to endothelial cells,
potentially linking the V2-expressing U87 cells with endothelial
cell recruitment for blood vessel formation. We conﬁrmed these
results by co-culturing the V2- or vector-transfected U87 cells with
YPEN rat endothelial cells and obtained a similar result (Fig. 3B,
Supplementary Fig. S2).
As an angiogenic assay, we then tested whether V2-expressing
U87 cells could facilitate the formation of tube-like structures in
Matrigel. The V2- and vector-transfected cells were mixed with
YPEN cells and cultured in Matrigel, followed by examination of
tube-like structure formation. We found that YPEN cells formed
complex tube-like structures when mixed with the V2 cells, which
did not occur in culture with the control cells (Fig. 3C). Analysis of
tube length and tube complexity was performed by ImageJ soft-
ware. Both measures of tube formation were signiﬁcantly in-
creased when endothelial cells were cultured with V2-expressing
tumor cells. Typical photographs of tube-like structures are shown
(Fig. 3D). Similar results were obtained with EOMA cells (Fig. 3E).
These results indicated that the V2-expressing cells were better
able to facilitate the production of tube-like structures through
the recruitment of endothelial cells. Through the release of adhe-
sion factors and proangiogenic signals, versican V2 may be a criti-
cal mediator of tumor angiogenesis.
3.4. V2 upregulates ﬁbronectin expression
We next analyzed levels of ﬁbronectin, an adhesion molecule,
by Western blot. Our results showed that the V2-expressing cells
expressed much higher levels of ﬁbronectin than the control
cells (Fig. 4A). Increased levels of ﬁbronectin were also detected
in the medium of the V2-culture (Fig. 4B). Tumor lysates were
subject to Western blot analysis for ﬁbronectin levels, and we
conﬁrmed that the tumor lysates derived from the V2-transfec-
ted cells showed higher levels of ﬁbronectin than from the con-
trol cells (Fig. 4C). Immunohistochemistry conﬁrmed this result
(Fig. 4D). Our results suggested that the versican V2 isoform
might up-regulate ﬁbronectin expression and enhance interac-
tion of tumor cells and endothelial cells, leading to increased
angiogenesis.
To test whether ﬁbronectin played a role in mediating V2 func-
tions, we used a siRNA approach to silence ﬁbronectin expression.
Cells transfected with four siRNA constructs targeting ﬁbronectin
were found to produce lower levels of ﬁbronectin (Fig. 4E). The
cells transfected with one of the siRNA constructs (siFN-32) or a
control vector were subjected to tube-like structure formation as-
say. The experiment indicated that cells transfected with siRNA
targeting ﬁbronectin displayed decreased complexity of tube-like
structure as compared with cells transfected with the V2 construct(Fig. 4F). A similar result was obtained with EOMA cells. Silencing
ﬁbronectin expression led to a decreased formation of tube-like
structures (Fig. 4G), which could be clearly observed by light
microscopy (Fig. 4H). These results indicated that ﬁbronectin
played an important role in mediating versican V2 function associ-
ated with angiogenesis.
Both versican and ﬁbronectin are extracellular molecules and
play important roles in enhancing cell adhesion. Although all vers-
ican isoforms contain the N-terminal G1 domain and a C-terminal
G3 domain, the expression and functions of each isoform appear to
be differentially regulated. Previous studies have demonstrated
that the V1 isoform can enhance cell proliferation while the V2 iso-
form can inhibit cell growth [7]. The V1 isoform can also stimulate
tumor growth [34]. However, the effect of the V2 isoform in tumor
development has not yet been elucidated. Since the V2 isoform has
been shown to be the primary isoform expressed in the mature
brain, reports on versican expression and function in the brain
are likely referring to this isoform. In the brain, versican is mainly
expressed in the submeningeal layers of the cortex, around the
blood vessels, and in a layer of cerebellum where it is observed
to co-localize with tenascin and hyaluronan, two adhesion mole-
cules [2,35,36]. In brain tumors, versican is detected in the intersti-
tial tissues at the invasive margins, and in the perivascular elastic
tissues associated with tumor invasion [26]. Increased versican
immunostaining is detected in tumor blood vessels [29]. Elevated
versican expression is also observed in the mesenchymal tissues
between the invasive clumps of carcinoma cells at the margins of
inﬁltrating ductal carcinoma. Collectively, it is highly likely that
versican may play an important role in tumor development and
blood vessel formation. Because the versican V2 isoform is the pre-
dominant isoform in the mature brain, we investigated the role of
V2 isoform in tumor angiogenesis. Our study directly demon-
strated that versican V2 isoform promoted tumor angiogenesis.
This occurred through increased levels of interactions between tu-
mor cells and endothelial cells, facilitating the formation of tube-
like structures.
The ability of V2-expressing cells to survive under stressed con-
ditions (i.e. deprivation of serum from the medium) may be key to
its angiogenic role. Despite a reduced proliferative ability, the V2-
expressing cells were able to survive much better than the control
cells. This may be suggestive of a role for tumor side-population
cells and vasculogenic mimicry, although this awaits further
investigation.
Up-regulation of ﬁbronectin expression appears key in angio-
genesis. Fibronectin is an adhesion molecule playing a role in
angiogenesis [33]. Since the versican G3 domain has been shown
to bind to ﬁbronectin, the V2 isoform may play the role in angi-
ogenesis by up-regulating and binding to ﬁbronectin. To conﬁrm
this, we have demonstrated that silencing ﬁbronectin expression
by siRNA abolished V2’s effect in enhancing tube-like structure
formation. Taken together, our results demonstrated that the
versican V2 isoform played a role in tumor angiogenesis by
enhancing tumor cell survival, facilitating interactions between
tumor and endothelial cells leading to the formation of tube-like
structures, and up-regulating ﬁbronectin expression. Regulating
the versican V2 isoform and ﬁbronectin may be potential targets
for the intervention of tumorigenesis and angiogenesis in brain
cancer.
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